About us

Claire Lefranc is Co-Founder and CEO of Kondree, where her journey from legal strategist to biotech innovator has shaped every facet of the company’s work. Trained in law, her early career included the launch of two pioneering tech start-ups, the creation of a significant grass-roots movement supporting vulnerable populations during COVID, and a senior management role as a high-level negotiator in commercial and institutional real estate. These diverse experiences honed her ability to turn complex challenges into opportunities — a strength she brought with her when founding Kondree. Since becoming President in June 2021, she has secured key licences, built robust governance structures and made it her mission to focus Kondree on truly individualised health: enabling antioxidant profiling,
medical-software tools and personalised supplementation to bring science into day-to-day care. 
What distinguishes Claire is her dual aptitude: steely precision from her prior legal and business roles, combined with the courage to venture into uncharted scientific territory. She balances the financial structuring and legal complexity inherent in scaling a biotech company with compassion for patients and a long-term vision for driving innovation in the treatment of pathological oxidative stress. Under her leadership, Kondree has moved from concept to clinic, building bridges between laboratories, healthcare providers and patients.

Thomas Person is Chief Technology Officer of Kondree, where his passion for innovation and technological R&D drives the company’s digital architecture and industrial strategy. With nearly twenty years of experience in IT project management, Thomas built his career at RATP Group, where he led large-scale projects across identity management, cybersecurity, data systems and industrial innovation. He coordinated cross-functional teams on initiatives that introduced cutting-edge technologies — from artificial intelligence and predictive maintenance to the Internet of Things and Big Data — transforming operations and improving reliability across complex infrastructures. As Deputy IT Director for Research and Innovation, he spearheaded the exploration and industrialization of emerging technologies, aligning them with corporate strategy and operational priorities.
At Kondree, Thomas oversees the technological backbone of the company — from partner sourcing and system architecture to regulatory compliance and cybersecurity. He guides strategic choices on software design, R&D priorities and budget planning (OPEX and CAPEX), ensuring that Kondree’s digital and industrial ecosystems evolve in step with scientific innovation. What distinguishes Thomas is his ability to manage the technical complexity of advanced systems while turning innovation into secure, scalable and compliant solutions. His leadership ensures that Kondree’s IT infrastructure remains state-of-the-art in cybersecurity, agile in design, and fully aligned with the company’s mission to transform the treatment of pathological oxidative stress.

Christopher-Georges Lemesle is Chief Operating Officer of Kondree, bringing a decade of experience building complex partnerships and scaling programmes across continents to a fast-growing biotech and medtech environment. Before joining Kondree in July 2025, he worked with the United Nations and other international organisations managing a portfolio of up to USD 160 million per year and forging high-level partnerships with governments, multilateral institutions and major global corporations (including Mastercard, Coca-Cola, Novo Nordisk, Takeda Pharmaceuticals, IKEA, Toyota and FC Barcelona). These roles honed his ability to coordinate multidisciplinary teams, steer cross-border initiatives and navigate demanding financial, legal and regulatory frameworks across contienents.
Since joining Kondree, Christopher has focused on aligning scientific, financial and organisational priorities to support rapid growth and market entry. What distinguishes him is his ability to find innovative solutions at the intersection of complex systems, translate global partnership expertise into a start-up environment, and drive international expansion by forging relationships with clinics and physicians while anticipating the regulatory pathways critical to Kondree’s future. Drawing on his global experience, Christopher is helping Kondree build the infrastructure and regulatory pathways that will enable its personalized therapies for pathological oxidative stress to go from concept to clinic.

Dr. Nicolas Tartrat is Chief Medical Officer of Kondree, where his frontline expertise in anesthesia and critical care shapes the company’s path toward personalised therapies targeting pathological oxidative stress. As an Anesthesiologist-Intensivist (M.D.), he has spent more than a decade caring for patients facing the most severe physiological challenges — from major cardiac surgery to pediatric intensive care — where restoring homeostasis can mean the difference between life and death.
Educated at Université Paris-Saclay and trained within the Assistance Publique – Hôpitaux de Paris network, Nicolas also holds a Master’s degree in Biology and Innovative Therapies, along with specialised credentials in artificial ventilation, extracorporeal circulation and cardiovascular ultrasound. This hands-on clinical experience has given him deep insight into mitochondrial dysfunction and oxidative stress — the very mechanisms Kondree is tackling.
At Kondree, Nicolas brings both vigilance and vision to innovation. He ensures that every scientific and digital breakthrough — from biomarker profiling to medical-software tools — aligns with real patient needs, clinical safety and medical excellence. Driven by a passion for translating advanced science into meaningful progress, he is helping turn Kondree’s mission into a new standard of precision care for individuals affected by oxidative stress–related disease.

Professor Marie-Christine Dabauvalle is Scientific Advisor to Kondree, where her deep understanding of cellular life aligns with the company’s mission to transform care for patients affected by oxidative-stress-related diseases. A recognized specialist in cell biology, with a focus on the dynamics of the nuclear envelope, she has devoted much of her career to elucidating the molecular mechanisms of hereditary muscular dystrophies — in particular, the role of nuclear components and mitochondrial dysfunction in conditions such as FSHD.
Now Professor of Cell Biology at the University of Würzburg, Marie-Christine holds a PhD in Biochemistry from Université Paris VII and conducted her research at the German Cancer Research Center and the European Molecular Biology Laboratory in Heidelberg. Her pioneering work has highlighted the involvement of nuclear envelope proteins in skeletal and cardiac myopathies, as well as their role in oxidative-stress-related cellular imbalances. In 2020, she received the Julius-Maximilian Medal of Merit in recognition of her lifelong scientific contribution.
A mentor to many generations of researchers, Marie-Christine has led international projects, served as an expert reviewer for national and international publications and research programs, and is frequently invited to speak at major scientific and public events across Europe, the Middle East and beyond — advocating for a gender-sensitive approach in science and healthcare. At Kondree, she helps guide scientific strategy and strengthen the bridge between academic research and therapeutic innovation. Her scientific rigor and humanity ensure that Kondree’s advances remain both inclusive and profoundly centered on patient wellbeing.

Pr. Dalila Laoudj-Chenivesse is Scientific Advisor to Kondree, bringing decades of pioneering research at the intersection of muscle diseases, oxidative stress, and personalized therapeutic innovation. She is Professor of Physiology at the University of Montpellier’s Faculty of Medicine and a senior researcher within the CNRS/INSERM PHYMEDEXP laboratory, where she leads cutting-edge work on neuromuscular disorders, particularly facioscapulohumeral dystrophy (FSHD).

Holder of a PhD in Genetics and Microbiology from Université Paris XI (Orsay), Dalila has built an internationally recognized scientific career, leading clinical studies, mentoring scientific talent, and securing major national and European research collaborations. Her work has elucidated how mitochondrial dysfunction and pathological oxidative stress contribute to FSHD disease progression — mechanisms that are central to Kondree’s mission. She is also an experienced health innovator: co-founder of ICDD, laureate of the French Ministry of Innovation (OSEO-ANVAR), and inventor on multiple patents, including a decision-tree model designed to individualize antioxidant supplementation based on biomarker profiling.

At Kondree, Dalila provides scientific leadership across clinical strategy, biomarker discovery, and regulatory-grade medical decision tools, ensuring that every advancement is grounded in rigorous physiology and real patient benefit. Guided by a commitment to patient well-being, she is helping Kondree build the scientific foundations for a new era of precision care in oxidative stress-related diseases.